1. Introduction {#sec1-jcm-08-01293}
===============

Use of antimicrobial agents has reduced mortality in infectious diseases. However, excessive antibiotic use has caused development of antimicrobial resistance (AMR) in bacteria \[[@B1-jcm-08-01293],[@B2-jcm-08-01293]\]. Infection with an antimicrobial resistant organism has become a major public health concern due to its difficulty to treat, resulting in an increase in hospital stays, cost, and mortality \[[@B3-jcm-08-01293]\]. While antimicrobial resistant organisms have been increasing rapidly, only a few new drugs for combating these pathogens have been developed \[[@B4-jcm-08-01293]\].

An antimicrobial stewardship program (ASP) is one of the most important strategies for preventing AMR \[[@B5-jcm-08-01293],[@B6-jcm-08-01293]\]. In addition, an ASP can improve clinical outcomes in patients while reducing adverse drug reactions \[[@B7-jcm-08-01293]\]. With the proven advantages of ASPs, the necessity for such programs has been realized in most hospitals, regardless of bed size or teaching status. The importance of the role of an infectious disease specialist (IDS) in implementing a successful ASP has been proven through previous studies \[[@B8-jcm-08-01293],[@B9-jcm-08-01293],[@B10-jcm-08-01293]\]. However, most of these studies evaluated the role of an IDS and the effects of an ASP in large, academic hospitals.

On the other hand, only a few studies have reported successful implementation of ASPs in non-academic community (NAC) hospitals \[[@B11-jcm-08-01293],[@B12-jcm-08-01293]\]. NAC hospitals would need modified strategies to implement ASPs because they have fewer resources to allocate to them than do large or teaching hospitals. In Korea, while most NAC hospitals have been challenged to implement ASPs, most of them do not have facility leadership support available. Most IDSs have worked in large, academic hospitals, and they are rarely hired by NAC hospitals.

Since the Middle East respiratory syndrome-coronavirus outbreak in 2015, the Korean government has been encouraging hospitals to employ infection control doctors by policy. Consequently, the Korean National Health Insurance Service now reimburses infection control costs on the condition that doctors and nurses be allocated for infection control in hospitals with more than 300 beds \[[@B13-jcm-08-01293]\]. Accordingly, there has been a recent increase in the number of IDSs working as infection control doctors in NAC hospitals. These IDSs are expected to play a major role in ASPs; however, this has not yet been fully evaluated.

We hypothesized that having an IDS could be a potential solution for implementing a successful ASP in a resource-limited setting. The aim of this study was, therefore, to evaluate the impact of an IDS-led ASP through the changes in the amount of antibiotic use and the rate of multidrug-resistant organism (MDRO) acquisition at a resource-limited NAC hospital in Korea.

2. Materials and Methods {#sec2-jcm-08-01293}
========================

2.1. Study Population and Data Collection {#sec2dot1-jcm-08-01293}
-----------------------------------------

We conducted a retrospective study at Kimpo Woori Hospital, a NAC hospital with 402 beds in Korea. All patients admitted to the hospital between June 2015 and August 2018 were eligible to participate. Of these, we included 578 patients who had positive cultures for methicillin-resistant *Staphylococcus aureus* (MRSA), multidrug-resistant *Acinetobacter baumannii* (MDRAB), and multidrug-resistant *Pseudomonas aeruginosa* (MDRPA) from any type of specimen received at least 48 h after admission. Multidrug-resistance was defined as resistance to at least one antibiotic between carbapenems, aminoglycosides, and fluoroquinolones.

Data of all patients were included for statistical analysis only once for each organism. We collected the data on clinical characteristics from electronic medical records. Patients' underlying comorbidities were defined using the International Classification of Diseases, 10th revision. Microorganisms were identified using a VITEK-2 automated bacterial identification system (bioMerieux, Marcy-I'Etoile, France). Antimicrobial susceptibility testing was interpreted using the Clinical and Laboratory Standards Institute guidelines \[[@B14-jcm-08-01293]\]. This study was approved by the Institutional Review Board of Yonsei University Health System Clinical Trial Center (approval number 4-2019-0519), and the protocol adhered to the tenets of the Declaration of Helsinki. Since the study was retrospective in nature and the study participants were anonymized, the Institutional Review Board waived the requirement for written consent from the patients.

2.2. Amount of Antibiotic Consumption {#sec2dot2-jcm-08-01293}
-------------------------------------

We collected the data for monthly antibiotic prescriptions to evaluate the trend in the amount of antibiotic use. This study included only parenteral antibiotics and excluded oral or topical agents. Classification and defined daily doses (DDDs) of antibiotics were determined according to the World Health Organization Anatomical Therapeutic Chemical Classification \[[@B15-jcm-08-01293]\]. We grouped antibiotics as follows: aminoglycosides, 1st/2nd and 3rd/4th generation cephalosporins, carbapenems, glycopeptides, fluoroquinolones, penicillins, and other antibiotics, including linezolid, colistin, and tigecycline.

2.3. The Intervention {#sec2dot3-jcm-08-01293}
---------------------

In March 2015, the hospital implemented an initial ASP led by an internal medicine physician without infectious disease training. Associated polices were defined, and bylaws were introduced throughout the hospital. The policies mainly aimed to limit inappropriate use of prophylactic antibiotics for surgery, which restricted prescription of 3rd generation cephalosporins and aminoglycoside for surgery. Additionally, computerized prescription monitors produced pop-up alarms when physicians continued to prescribe antibiotics designated as restricted, such as linezolid, colistin, tigecycline, glycopeptides, and carbapenems, for more than 3 days. The pop-up alarm system did not restrict or monitor prescription of antibiotics designated as restricted.

The hospital hired an IDS for the first time in March 2017. Three months later, the IDS began to lead the ASP. The ASP was enforced to reduce MDROs and the amount of antibiotic use in the hospital beginning in June 2017. The IDS intended to reduce the use of inappropriate antibiotic combinations, such as overlap in antimicrobial coverage, as well as inappropriate use of prophylactic antibiotics for surgery. Furthermore, he endeavored to increase the appropriate use of carbapenems, glycopeptides, anti-pseudomonal cephalosporins (ceftazidime and cefepime), and other antibiotics (linezolid, colistin, and tigecycline). All physicians were required to consult the IDS for prescription of antibiotics designated as restricted. The IDS assessed the appropriateness of using those antibiotics and recommended the proper dosage and interval and optimal duration of treatment through consultations with the physicians. He also checked the results of culture studies at 5 to 7 days after the approval of antibiotic use and made the decision whether to continue a prescription.

2.4. Statistical Analysis {#sec2dot4-jcm-08-01293}
-------------------------

The change in pattern of antibiotic consumption and MDRO acquisition in accordance with the IDS-led ASP between June 2015 and August 2018 was analyzed using an interrupted time series \[[@B16-jcm-08-01293]\]. After implementation of the intervention in June 2017, we set a transition period of three months to allow the intervention process to stabilize. This study divided the time series into two segments, pre- and post-intervention. We used segmented regression analysis to assess the longitudinal effect of the IDS-led ASP. Parameters used in segmented regression analysis were defined as follows. The level was considered the value of a measure at the beginning of a time segment. The trend was considered the rate of change for the measure during the given time interval. The level change after intervention was considered the average value of change after intervention, reflecting the immediate effect of the intervention. The trend change after intervention was considered to be the change in slope during the period after intervention, constituting a gradual change during the segment. The Durbin--Watson statistic was used to test for the presence of autocorrelation, and we verified no serious autocorrelation. We compared the clinical characteristics of each patient with MDRO acquisition for one year before and after the intervention using either the independent t-test or the Chi-square test.

Statistical analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC, USA.) or R software version 3. Statistical significance was considered as *p* \< 0.05.

3. Results {#sec3-jcm-08-01293}
==========

3.1. Clinical Characteristics of Patients {#sec3dot1-jcm-08-01293}
-----------------------------------------

Between June 2016 and August 2018, the most prevalent organism reported in clinical specimens was MRSA (n = 362), followed by MDRAB (n = 139) and MDRPA (n = 77) ([Table 1](#jcm-08-01293-t001){ref-type="table"}). Clinical characteristics of patients with hospital-acquired MRSA and MDRPA acquisition did not differ statistically before and after the intervention. Among the patients with MDRAB acquisition, the proportion of those having solid cancer or cardiovascular disease were higher in the post-intervention period than in pre-intervention.

3.2. Amount of Antibiotic Consumption {#sec3dot2-jcm-08-01293}
-------------------------------------

Total antibiotic use changed from 698.82 ± 74.41 DDD/1000 patient-days (PDs) to 602.09 ± 69.94 DDD/1000 PDs during study period ([Table S1](#app1-jcm-08-01293){ref-type="app"}). Following the intervention, amount of most antibiotic use decreased, except 1st/2nd generation cephalosporin, which increased from 93.76 ± 10.13 DDD/1000 PDs to 96.2 ± 14.15 DDD/1000 PDs. We demonstrated antibiotic consumption patterns between June 2015 and August 2018 in [Figure 1](#jcm-08-01293-f001){ref-type="fig"}.

According to segmented regression analysis, there was a decreasing trend in the amount of aminoglycoside and quinolone consumption before the intervention (*p* \< 0.001 for each antibiotic) ([Table 2](#jcm-08-01293-t002){ref-type="table"}). Following the intervention, decreases in both level and trend of the total amount of antibiotics consumed were not statistically significant. However, the intervention had a prominent effect on the use of antibiotics designated as restricted. Just after the transition period, among the antibiotics designated as restricted, there was an immediate reduction in the use of carbapenems (coefficient −16.108, *p* = 0.033), glycopeptides (coefficient −12.287, *p* = 0.012), and other antibiotics (coefficient −16.092, *p* = 0.043). Although significant immediate change was not observed in the amount of 3rd/4th generation cephalosporins use, including that of ceftazidime/cefepime, there was a significant decreasing trend following the intervention as compared with that during pre-intervention (coefficient −8.459, *p* = 0.004). In addition to the immediate response, use of carbapenems showed a significant decreasing trend after the intervention (coefficient −2.029, *p* = 0.027). Penicillins were not subject to restriction, but their use decreased immediately after the intervention. Following an immediate reduction after the transition period, there was no significant change in the trend of use of glycopeptides, penicillins, and other antibiotics.

3.3. Incidence of MDRO Acquisition {#sec3dot3-jcm-08-01293}
----------------------------------

From June 2015 to May 2017 (the period before the intervention), the incidence of MDRO acquisition was 1.381, 0.213, and 0.777/1000 PDs in MRSA, MDRAB, and MDRPA, respectively ([Table S2](#app1-jcm-08-01293){ref-type="app"}). The incidence of MRSA and MDRAB acquisition decreased following the intervention (1.06/1000 PDs in MRSA and 0.15/1000 PDs in MDRAB). However, during the same period, there was an increase in the incidence of MDRPA acquisition (0.32/1000 PDs). The incidence of MDRO acquisition in patients admitted to the hospital during the study period is presented in [Figure 2](#jcm-08-01293-f002){ref-type="fig"}.

In segmented regression analysis, a significant increasing trend was observed in the incidence of MRSA acquisition before the intervention (coefficient 0.03, *p* \< 0.001) ([Table 3](#jcm-08-01293-t003){ref-type="table"}). Immediately following the transition period, the estimated incidence of MRSA acquisition decreased (coefficient −0.71, *p* \< 0.001). There was no significant changing trend in the incidence of MDRAB and MDRPA before the intervention. The incidence of MDRAB acquisition dropped after the transition period (coefficient −0.62, *p* = 0.014); however, MDRPA acquisition increased (coefficient 0.21, *p* = 0.035). There was no significant trend change in the incidence of acquisition of each MDRO after the intervention.

4. Discussion {#sec4-jcm-08-01293}
=============

Here, we have demonstrated the impact of an IDS on the implementation of an ASP at a resource-limited NAC hospital in Korea. The intervention had an immediate effect on the reduction in antibiotics designated as restricted. Moreover, there was a continuous decreasing trend in the use of some antibiotics after the intervention. In addition, along with the decreased amount of antibiotic use, the incidence of MRSA and MDRAB acquisition decreased immediately following the IDS-led ASP without a significant trend change after the immediate effect.

Data on antibiotic use in NAC hospitals are limited in Korea. We previously reported on the amount of antibiotic use in a large, university-affiliated hospital \[[@B17-jcm-08-01293]\]. Compared with the rate at this major teaching hospital, our current study demonstrated a similar usage rate of antibiotics in the NAC hospital. Other studies have also reported that hospital size is not important in predicting the amount of antibiotic use \[[@B18-jcm-08-01293],[@B19-jcm-08-01293]\]. Given these findings, regardless of bed size or medical school affiliation, all hospitals should be required to implement ASPs. However, the majority of Korean NAC hospitals still do not have these programs because of insufficient human, financial, and information technology resources as compared with large, academic medical centers. For example, a pharmacist should be involved in an ASP; however, most Korean NAC hospitals do not have a staff member with drug expertise as one of the core elements for a successful hospital ASP \[[@B20-jcm-08-01293]\]. In addition, although NAC hospitals do implement ASPs, there are barriers to the success of these programs. First, a large proportion of patients in NAC hospitals come from long-term care facilities; therefore, they are likely to suffer from recurrent aspiration pneumonia or severe decubitus ulcers, which result in an increased chance of antibiotic use \[[@B21-jcm-08-01293]\]. Second, compared to in large academic hospitals, reducing antibiotic use, especially well-reimbursed drugs, may not be financially beneficial in NAC hospitals \[[@B12-jcm-08-01293]\]. Therefore, ASPs may not be receiving sufficient support from hospital leadership.

Having an IDS could be a potential solution for implementation of a successful ASP at disadvantaged NAC hospitals. IDS consultation can reduce antibiotic use through the discontinuation of inappropriate antibiotics and an increase in appropriate antibiotic use by changing to narrow spectrum antibiotics \[[@B22-jcm-08-01293]\]. In addition, involvement of an IDS in clinical practice has been associated with improved patient outcomes \[[@B23-jcm-08-01293]\]. The skill set of an IDS engenders trust in other physicians, making them receptive to IDS suggestions for appropriate antibiotic use. In this study, the use of 1st/2nd generation cephalosporins tended to increase after the intervention (coefficient 1.891, *p* = 0.061), although these results were not statistically significant. This may have been caused by the change made by the IDS from empirical antibiotics that had been improperly used to appropriate antibiotics.

Similar studies have been conducted in small NAC hospitals with fewer than 200 beds. In these studies, ASPs have also been proven to reduce antibiotic use, lower medical costs, and improve antibiotic susceptibilities to specific pathogens \[[@B24-jcm-08-01293],[@B25-jcm-08-01293],[@B26-jcm-08-01293],[@B27-jcm-08-01293]\]. Even though IDSs spent much less time on the ASP than that in our study, they demonstrated successful results after implementation of ASP. However, key differences exist in our study compared to these other studies. First, most of the hospitals had pharmacists who were dedicated to the ASP and facilitated the intervention, but we did not have a pharmacist as a member of the ASP team because of the lack of available pharmacists in Korean NAC hospitals. Second, it takes less time to develop and maintain an ASP in smaller hospitals. Stenehjem et al. \[[@B12-jcm-08-01293]\] reported that the average time spent on the ASP is 5--10 hours per week in hospitals with 70--150 beds. In contrast, in our study the IDS was required to work full time in the hospital, which has 402 beds, and dedicate the most time to ASP activities. In addition, a low volume of patients and staff members means that once IDS-led ASPs are well established in smaller NAC hospitals, we can expect more rapid effects and better compliance than in larger NAC hospitals. Therefore, we think that this study, conducted in moderate-sized, resource-limited NAC hospital, is worthwhile.

There are multiple factors associated with the development of AMR. Several studies have shown strong evidence suggesting that an effective ASP can reduce the prevalence of AMR, as well as antibiotic use \[[@B10-jcm-08-01293],[@B28-jcm-08-01293],[@B29-jcm-08-01293],[@B30-jcm-08-01293]\]. Our study also shows that an IDS-led ASP can effect a reduction in AMR. We evaluated the incidence of MRSA, MDRAB, and MDRPA acquisition as indicators of AMR. In Korea, these pathogens are not only isolated frequently in clinical specimens, but also cause relevant infections in clinical practice. About 66% of *Staphylococcus aureus* has methicillin resistance, and the carbapenem resistance of *Acinetobacter baumannii* and *Pseudomonas aeruginosa* are 85% and 35%, respectively \[[@B31-jcm-08-01293]\]. However, we were unable to evaluate the incidence of carbapenem-resistant *Enterobacteriaceae* (CRE), because there were few cases of hospital-acquired CRE in the facility studied. Most CRE cases were confirmed in specimens collected prior to 48 h after admission.

A limitation of this study is that an infection control program could be a confounding factor for a decrease in the incidence of MDRO acquisition. However, this factor is unlikely to affect our results. The IDS spent some time meeting with the infection control team---which had been in existence and was doing well in the hospital before he arrived---to implement infection control activities. There was no significant change in the methods of the infection control program. For example, the main strategy for hand hygiene was education, monitoring, and feedback during the study period, and the performance rate was maintained at 81.3% to 88.4%. Another limitation was the immediate increase in the incidence of MDRPA acquisition despite a significant decrease in carbapenem use. A previous study showed that reduced carbapenem use was associated with a decrease in carbapenem resistance in *Pseudomonas aeruginosa* \[[@B28-jcm-08-01293]\], although we did not observe the same results. However, although there was no statistical significance, incidence of MDRPA acquisition had decreased in slope following the intervention.

5. Conclusions {#sec5-jcm-08-01293}
==============

ASP is an effective strategy to prevent or slow the development of MDROs. However, it is difficult for NAC hospitals to implement a successful ASP due to the lack of multidisciplinary resources. We have shown that an IDS could be a potential solution for successful implementation of an ASP in resource-limited settings. Our findings should, however, be verified in different settings, such as smaller institutions, thus facilitating the need for further study.

We extend our gratitude to medical staffs in Kimpo Woori hospital for their cooperation in the antimicrobial stewardship program.
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jcm-08-01293-t001_Table 1

###### 

Clinical characteristics of patients with hospital-acquired multidrug-resistant organisms between June 2016 and August 2018.

  Variables                                     Methicillin-Resistant *Staphylococcus aureus*   Multidrug-Resistant *Pseudomonas aeruginosa*   Multidrug-Resistant *Acinetobacter baumannii*                                                                 
  --------------------------------------------- ----------------------------------------------- ---------------------------------------------- ----------------------------------------------- ------------ ------------ --------- ------------ ------------ ---------
  Age, years (IQR)                              77 ± 13.6                                       75 ± 15.98                                     0.184                                           77 ± 13.33   73 ± 15.13   0.26      76 ± 14.26   77 ± 11.34   0.73
  Male, *n* (%)                                 129 (59.5)                                      97 (66.9)                                      0.152                                           16 (48.5)    25 (56.8)    0.468     38 (32.2)    7 (33.3)     0.919
  Antibiotic use in the past 30 days, *n* (%)   166 (76.5)                                      95 (65.5)                                      0.065                                           27 (81.8)    40 (90.9)    0.291     107 (90.7)   18 (85.7)    0.536
  Comorbidities, *n* (%)                                                                                                                                                                                                                                     
  Diabetes                                      73 (33.6)                                       41 (28.3)                                      0.282                                           13 (39.4)    10 (22.7)    0.114     37 (31.4)    8 (38.1)     0.543
  Solid cancer                                  34 (15.7)                                       28 (19.3)                                      0.278                                           6 (18.2)     7 (15.9)     0.792     21 (17.8)    8 (38.1)     0.044
  Hematologic malignancy                        1 (0.5)                                         2 (1.4)                                        0.567                                           1 (3.0)      1 (2.3)      \>0.999   1 (0.9)      0 (0.0)      \>0.999
  Solid organ transplantation                   0 (0.0)                                         0 (0.0)                                        \-                                              0 (0.0)      0 (0.0)      \-        0 (0.0)      0 (0.0)      \-
  Hematologic stem cell transplantation         0 (0.0)                                         1 (0.7)                                        0.401                                           0 (0.0)      1 (2.3)      \>0.999   0 (0.0)      0 (0.0)      \-
  Rheumatologic disease                         4 (1.8)                                         2 (1.4)                                        \>0.999                                         0 (0.0)      0 (0.0)      \-        0 (0.0)      0 (0.0)      \-
  Cardiovascular disease                        139 (64.1)                                      96 (66.2)                                      0.674                                           20 (60.6)    28 (63.6)    0.786     73 (61.9)    18 (85.7)    0.034
  Chronic obstructive pulmonary disease         33 (15.2)                                       26 (17.9)                                      0.492                                           2 (6.1)      8 (18.2)     0.174     18 (15.3)    5 (23.8)     0.344
  Renal Disease                                 60 (27.7)                                       42 (29.0)                                      0.785                                           6 (18.2)     7 (15.9)     0.792     30 (25.4)    6 (28.6)     0.762
  Liver disease                                 45 (20.7)                                       32 (22.1)                                      0.762                                           4 (12.1)     9 (20.5)     0.334     18 (15.3)    3 (14.3)     \>0.999
  HIV infection                                 0 (0.0)                                         0 (0.0)                                        \-                                              0 (0.0)      0 (0.0)      \-        0 (0.0)      0 (0.0)      \-
  Hemodialysis                                  16 (7.4)                                        10 (6.9)                                       0.863                                           2 (6.1)      6 (13.6)     0.454     8 (6.8)      2 (9.5)      0.648
  Neutropenia                                   0 (0.0)                                         1 (0.7)                                        0.401                                           0 (0.0)      0 (0.0)      \-        0 (0.0)      0 (0.0)      \-
  Steroid therapy                               16 (7.4)                                        10 (6.9)                                       \>0.999                                         2 (6.1)      2 (4.6)      0.347     14 (11.9)    2 (9.5)      \>0.999
  Immunosuppressive therapy                     0 (0.0)                                         0 (0.0)                                        \-                                              0 (0.0)      0 (0.0)      \-        0 (0.0)      0 (0.0)      \-
  Chemotherapy                                  0 (0.0)                                         3 (2.1)                                        0.064                                           0 (0.0)      1 (2.3)      \>0.999   0 (0.0)      0 (0.0)      \-
  Radiotherapy                                  0 (0.0)                                         0 (0.0)                                        \-                                              0 (0.0)      0 (0.0)      \-        0 (0.0)      0 (0.0)      \-

Note: IQR, interquartile range; HIV, human immunodeficiency virus.

jcm-08-01293-t002_Table 2

###### 

Segmented regression model predicting monthly daily defined dose per 1000 patient-days in the hospital.

  Antibiotics                         Coefficient   Standard Error   *p*-Value
  ----------------------------------- ------------- ---------------- -----------
  Aminoglycosides                                                    
  Baseline level                      22.0256       0.9929           
  Baseline trend                      −0.3305       0.0695           \<0.001
  Level change after intervention     0.8123        1.7243           0.641
  Trend change after intervention     −0.2064       0.2089           0.331
  1st/2nd generation cephalosporins                                  
  Baseline level                      101.9253      4.6246           
  Baseline trend                      −0.6535       0.3237           0.052
  Level change after intervention     1.9191        8.0315           0.813
  Trend change after intervention     1.891         0.9732           0.061
  3rd/4th generation cephalosporins                                  
  Baseline level                      177.211       13.0193          
  Baseline trend                      1.7935        0.9112           0.058
  Level change after intervention     11.108        22.6103          0.627
  Trend change after intervention     −8.4598       2.7399           0.004
  Ceftazidime/cefepime                                               
  Baseline level                      66.3764       8.7921           
  Baseline trend                      0.5003        0.6153           0.422
  Level change after intervention     −7.0211       15.269           0.649
  Trend change after intervention     −5.663        1.8503           0.004
  Carbapenems                                                        
  Baseline level                      39.3779       4.1486           
  Baseline trend                      0.4704        0.2903           0.115
  Level change after intervention     −16.1077      7.2047           0.033
  Trend change after intervention     −2.0287       0.8731           0.027
  Glycopeptides                                                      
  Baseline level                      35.0324       2.6622           
  Baseline trend                      0.1151        0.1863           0.541
  Level change after intervention     −12.2869      4.6233           0.012
  Trend change after intervention     −0.885        0.5602           0.124
  Penicillins                                                        
  Baseline level                      140.8157      12.7416          
  Baseline trend                      0.5614        0.8917           0.533
  Level change after intervention     −46.7517      22.128           0.043
  Trend change after intervention     4.2492        2.6814           0.123
  Fluoroquinolones                                                   
  Baseline level                      115.0862      6.0155           
  Baseline trend                      −1.8856       0.421            \<0.001
  Level change after intervention     4.1865        10.447           0.691
  Trend change after intervention     1.0813        1.2659           0.399
  Other antibiotics                                                  
  Baseline level                      64.8456       4.395            
  Baseline trend                      0.1295        0.3076           0.677
  Level change after intervention     −16.0924      7.6328           0.043
  Trend change after intervention     0.185         0.9249           0.843
  Total antibiotics                                                  
  Baseline level                      696.3197      31.5014          
  Baseline trend                      0.2003        2.2046           0.928
  Level change after intervention     −73.2129      54.7076          0.19
  Trend change after intervention     −4.1733       6.6293           0.536

jcm-08-01293-t003_Table 3

###### 

The incidence of multidrug-resistant organisms acquisition among patients in the hospital over time using segmented regression analysis.

  Multidrug-Resistant Organisms                   Coefficient   Standard Error   *p*-Value
  ----------------------------------------------- ------------- ---------------- -----------
  Methicillin-resistant *Staphylococcus aureus*                                  
  Baseline level                                  1.05          0.10             
  Baseline trend                                  0.03          0.01             0.001
  Level change after intervention                 −0.71         0.18             \<0.001
  Trend change after intervention                 −0.02         0.02             0.439
  Multidrug-resistant *Pseudomonas aeruginosa*                                   
  Baseline level                                  0.19          0.06             
  Baseline trend                                  0.002         0.004            0.628
  Level change after intervention                 0.21          0.10             0.035
  Trend change after intervention                 −0.02         0.01             0.082
  Multidrug-resistant *Acinetobacter baumannii*                                  
  Baseline level                                  0.85          0.13             
  Baseline trend                                  −0.01         0.01             0.569
  Level change after intervention                 −0.62         0.24             0.014
  Trend change after intervention                 0.02          0.03             0.588
